Jump to content

High-Throughput Identity Testing of Oligonucleotide Therapeutics Using a Fully Automated, Sample-Specific Data Workflow

CASSS-MS 2023, Chicago, IL, USA
September 5, 2023

Nucleic acid-based biotherapeutics and vaccines comprise diverse modalities such as mRNA, siRNA, antisense oligos (ASOs), and CRISPR/Cas, and offer many outstanding therapeutic characteristics (high specificity, functional diversity, easy adjustment). Although oligonucleotides are comparable to small-molecule pharmaceuticals, their complex structures and multistep synthesis processes often lead to the generation of impurities and degradation products. Consequently, oligonucleotide drugs require stringent quality control and impurity identification, with advanced methods for analysis, characterization, and quantitation. We present a fully automated data processing, analysis, and reporting workflow enabling high-throughput identity testing of oligonucleotide therapeutics.

We present a fully automated data processing workflow capable of processing MS data from any instrument that enables sample-specific identity confirmation of thousands of oligonucleotide therapeutics per day.

Request Resource

By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Genedata privacy policy